Last reviewed · How we verify
Placebo Drink + Moxifloxacin Capsule
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Bacterial infections (respiratory tract, skin and soft tissue, intra-abdominal, complicated skin infections).
At a glance
| Generic name | Placebo Drink + Moxifloxacin Capsule |
|---|---|
| Sponsor | University of the Pacific |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase; Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of aerobic and anaerobic bacteria. The placebo drink component serves as a control vehicle in this formulation.
Approved indications
- Bacterial infections (respiratory tract, skin and soft tissue, intra-abdominal, complicated skin infections)
Common side effects
- Nausea
- Diarrhea
- Dizziness
- Tendinitis/tendon rupture
- QT prolongation
- Photosensitivity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Drink + Moxifloxacin Capsule CI brief — competitive landscape report
- Placebo Drink + Moxifloxacin Capsule updates RSS · CI watch RSS
- University of the Pacific portfolio CI